Home > Boards > US Listed > Biotechs > NorthWest Biotherapeutics (NWBO)

DCVax-L Model Positive on Primary Endpoint.

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Pyrrhonian Member Profile
 
Followed By 12
Posts 1,495
Boards Moderated 0
Alias Born 06/09/12
160x600 placeholder
Law Firm Kirby McInerney LLP Investigating Potential Claims on Behalf of Northwest Biotherapeutics, Inc. Stockholders "Business Wire" - 7/23/2014 7:13:00 PM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 7/22/2014 4:21:22 PM
NW BIO ANNOUNCES COMPLETION OF DCVAX®-DIRECT PHASE I TRIAL RECRUITMENT "PR Newswire (US)" - 7/16/2014 8:15:00 AM
The Law Firm of Levi & Korsinsky, LLP Launches an Investigation into Possible Violations of Federal Securi... "PR Newswire (US)" - 7/9/2014 6:23:00 PM
Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In Northwest Biotherapeutics, I... "PR Newswire (US)" - 7/4/2014 1:17:00 PM
Investigation of Northwest Biotherapeutics, Inc. Announced by Glancy Binkow & Goldberg LLP "Business Wire" - 7/1/2014 5:32:00 PM
Robbins Arroyo LLP Is Investigating the Officers and Directors of Northwest Biotherapeutics, Inc. on Behalf of Shareholders "PR Newswire (US)" - 7/1/2014 1:33:00 PM
The Law Firm of Levi & Korsinsky, LLP Launches an Investigation into Possible Violations of Federal Securi... "Business Wire" - 6/25/2014 4:50:00 PM
NW BIO REAFFIRMS DCVAX®-DIRECT CLINICAL TRIAL INTERIM DATA ANNOUNCEMENTS "PR Newswire (US)" - 6/20/2014 8:25:00 AM
Investigation on Behalf of Northwest Biotherapeutics, Inc. Investors Announced by Law Offices of Howard G.... "Business Wire" - 6/19/2014 4:32:00 PM
Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Northwest Biotherapeutics, Inc. "PR Newswire (US)" - 6/19/2014 2:30:00 PM
Investor Alert: Investigation into Northwest Biotherapeutics, Inc. Announced by Holzer & Holzer, LLC "Business Wire" - 6/19/2014 2:11:00 PM
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Northwest Biotherapeutics, Inc. - NWBO "PR Newswire (US)" - 6/19/2014 11:16:00 AM
NW BIO NAMED TO TWO RUSSELL INDEXES "PR Newswire (US)" - 6/16/2014 8:15:00 AM
DCVAX-DIRECT TRIAL UPDATE INDICATES FURTHER POSITIVE RESPONSES; 3 CASE STUDIES SHOW NO LIVE TUMOR CELLS IN INJECTED TUMORS "PR Newswire (US)" - 6/11/2014 8:15:00 AM
DCVAX®-L PHASE III TRIAL INITIATED IN GERMANY "PR Newswire (US)" - 6/10/2014 8:15:00 AM
NW BIO TO PRESENT AT JEFFERIES 2014 GLOBAL HEALTHCARE CONFERENCE "PR Newswire (US)" - 6/4/2014 11:23:00 AM
NW BIO REFUTES MORE FALSE CLAIMS BY FEUERSTEIN "PR Newswire (US)" - 5/29/2014 9:27:00 AM
NW BIO TO HOLD CONFERENCE CALL TO DISCUSS EARLY RESULTS OF DCVAX®-DIRECT ONGOING PHASE I/II TRIAL "PR Newswire (US)" - 5/27/2014 12:05:00 PM
EARLY POSITIVE RESPONSES SEEN IN OVER 50% OF DCVAX®-DIRECT PATIENTS TO DATE "PR Newswire (US)" - 5/27/2014 8:30:00 AM
Quarterly Report (10-q) "Edgar (US Regulatory)" - 5/15/2014 5:12:16 PM
NW BIO ANNOUNCES FIRST DATA FROM ONGOING DCVAX-DIRECT TRIAL "PR Newswire (US)" - 5/15/2014 8:00:00 AM
PRESENTATION ON NW BIO'S DCVAX-DIRECT TRIAL ANNOUNCED FOR ASCO ANNUAL MEETING "PR Newswire (US)" - 4/22/2014 8:15:00 AM
NW BIO CLOSES ON FIRST $15 MILLION OF FINANCING FOR SUBSTANTIAL EXPANSION OF EUROPEAN PRODUCTION CAPACITY "PR Newswire (US)" - 4/15/2014 1:11:00 PM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 4/14/2014 12:54:09 PM
Pyrrhonian   Friday, 04/18/14 07:09:04 PM
Re: None
Post # of 15896 
DCVax-L Model Positive on Primary Endpoint.


This was from alphapuppy a bit ago:

Quote:
Discloser: I am long this stock; I have no inside information; I am a clinical researcher.

Hypothesis 1: The Control Patients in the DCVax-L GBM trial should relapse at a rate similar to what was shown in the Stupp trial. The Stupp trial is the best GBM data available and represents the standard of care for GBM patients. In order to compare the Stupp Trial to the current DCVax-L trial control patients, however, one must review the eligibility requirements for each trial. The DCVax-L Trial only allows patients to enter the trial, if “surgical resection with the intent of a gross total or near gross total resection” can be completed. The Stupp Trial contained 17% patient who just had a biopsy only and another 44% of the patients who only had a partial resection. Extent of surgical resection is a major prognostic factor for these tumors and historical reviews have shown the degree which the various surgical procedures can change survival rates. The Median progression free survival (PFS) for all patients in the Stupp trial was 6.9 months. When one applies algebra proportions to correct for the differences in prognosis between the trials in terms of surgical extent, the likely median PFS for the control patients in the DCVax-L trial should be around 9 months.

Hypothesis 2: Given that we know the current number of events in the total DCVax-L trial at this time (first interim analysis) is 67, then one can model the control arm PFS to be similar to the corrected Stupp trial results and thus obtain an estimate for the probable number of events required in the control arm of the DCVax-L trial to give a 9 month median PFS. When one does this with a Kaplan Meier plot, one obtains a result of a minimum of 30 events in the control arm with the total number of patients in the control arm of 57. Then one can deduce that the number of events in the experimental arm for the DCVax-L trial would be 67-30 or 37 events.

Hypothesis 3: Using the derived 37 events in the experimental arm, one can model the experimental arm to be similar to the Stupp trial results but, in this case only allow for just 37 events out of 114 total patients in the DCVax-L experimental arm. When one does this with a Kaplan Meier plot, the median PFS for the experimental arm returns > 17.5 month median PFS in the DCVax-L experimental arm. When one applies log-rank and Wilcoxon significance testing to the two curves one obtains a significant result of p=<.0001 and p =.00015 respectively.

My best educated guess is that the DCVax-L trial is likely going to return a positive result on the primary end point given the information that we have currently available.


Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist